Cargando…
洛拉替尼特殊不良反应管理中国专家共识
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3(rd) generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411957/ https://www.ncbi.nlm.nih.gov/pubmed/36002192 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.39 |